Estadístiques de Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Visites totals

views
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date 201

Visites totals per mes

views
October 2024 0
November 2024 1
December 2024 0
January 2025 0
February 2025 0
March 2025 0
April 2025 0

Visites al fitxer

views
remon-cmr-nivo.pdf(legacy) 201
remon-cmr-nivo.pdf 31

Vistes principals per país

views
United States 134
United Kingdom 9
Australia 8
Germany 6
Spain 5
Brazil 4
Japan 4
China 3
Egypt 3
Greece 3
South Korea 3
Sweden 3
Canada 2
Czechia 2
Hong Kong SAR China 2
France 1
India 1
Italy 1
Malaysia 1
Serbia 1
Slovakia 1

Visites principals per ciutat

views
Ashburn 18
Fairfield 17
San Ramon 14
Redwood City 12
Mountain View 6
Menlo Park 5
Cambridge 4
Carapicuíba 4
Ridge 4
Tustin 4
Berkeley 3
Boardman 3
Leeds 3
Princeton 3
Seoul 3
Shenzhen 3
Tokyo 3
Bedworth 2
Cairo 2
Hong Kong 2
London 2
Los Angeles 2
Marblehead 2
Murcia 2
Sacramento 2
San Diego 2
Seattle 2
Sydney 2
Tallahassee 2
Thessaloníki 2
Albuquerque 1
Altamonte Springs 1
Ann Arbor 1
Arganda 1
Barcelona 1
Bethesda 1
Brisbane 1
Brooklyn 1
Charleston 1
Columbus 1
Kyoto 1
Maryborough 1
Middletown 1
Naples 1
Northolt 1
Patras 1
Petaling Jaya 1
Philadelphia 1
Pinjarra 1
Portland 1
Scarborough 1
Stockholm 1
Subotica 1
Tempe 1
Thane 1
Toronto 1
Valladolid 1
Wichita 1
Yellowknife 1